Stifel Starts Lexeo Therapeutics (LXEO) at Buy, 'Catalyst-Rich 2024'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Chardan Capital Markets Starts Lexeo Therapeutics (LXEO) at Buy
November 28, 2023 6:42 AM ESTChardan Capital Markets analyst Geulah Livshits initiates coverage on Lexeo Therapeutics (NASDAQ: LXEO) with a Buy rating and a price target of $23.00.
The analyst comments "
We initiate coverage of Lexeo Therapeutics with a Buy rating and a $23 PT on the potential of its AAV gene therapy (GT) pipeline to durably treat the underlying cause of disease in genetically defined forms of cardiomyopathy (CM) and Alzheimers disease (AD) representing sizable patient populations with high... More
RBC Capital Starts Lexeo Therapeutics (LXEO) at Outperform; 'Solid Team... Commercial Opportunity Just Validated By BIIB'
November 28, 2023 12:59 AM EST(Updated - November 28, 2023 6:54 AM EST)
RBC Capital analyst Luca Issi initiates coverage on Lexeo Therapeutics (NASDAQ: LXEO) with a Outperform rating and a price target of $22.00.
The analyst commented, "We are initiating at Outperform, Speculative Risk with a $22 PT given:... More
JPMorgan Starts Lexeo Therapeutics (LXEO) at Overweight
November 28, 2023 12:58 AM ESTJPMorgan analyst Tessa Romero initiates coverage on Lexeo Therapeutics (NASDAQ: LXEO) with a Overweight rating and a price target of $20.00.
For an analyst ratings summary and ratings history on Lexeo Therapeutics click here. For more ratings news on Lexeo Therapeutics click here.
Shares of Lexeo Therapeutics closed at $11.00 yesterday.
... More